Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David W. Mathes is active.

Publication


Featured researches published by David W. Mathes.


Transplantation | 2003

Split tolerance to a composite tissue allograft in a swine model.

David W. Mathes; Mark A. Randolph; Mario G. Solari; Jamal A. Nazzal; G. Petur Nielsen; J. Scott Arn; David H. Sachs; W. P. Andrew Lee

Background. The antigenicity of skin is a major obstacle to expanding human composite tissue transplantation. For example, multiple rejection episodes of the skin have been noted in clinical hand transplant patients. We have previously demonstrated tolerance to vascularized musculoskeletal allografts in major histocompatibility complex (MHC)-matched miniature swine treated with 12 days of cyclosporine. This regimen did not reproducibly lead to tolerance to subsequent frozen donor skin grafts. However, such skin grafts did not have a primary vascular supply. The aim of this study was to determine if tolerance to limb allografts with a vascularized skin component could be achieved with MHC matching and a 12-day course of immunosuppression. Methods. Hind limb grafts harvested with a 100 cm2 cutaneous paddle were transplanted heterotopically into six MHC-matched, minor antigen-mismatched miniature swine. All animals received a 12-day course of cyclosporine. One control animal was not immunosuppressed. Grafts were evaluated with biweekly biopsies and tissue viability determined by histologic analysis. To test for sensitization, frozen donor skin grafts were applied to all animals that survived to postoperative day 100. Results. All treated animals (n=6) were tolerant to their musculoskeletal allografts at the time of necropsy (>100 days) regardless of the status of the epidermis. One animal demonstrated tolerance to the skin for more than 180 days. The other five animals demonstrated prolonged survival of the epidermal portion of the graft. The control animal rejected the graft epidermis at 10 days postoperatively. Frozen donor skin grafts demonstrated accelerated rejection (<10 days) in three of the animals and led to simultaneous rejection of both the epidermis of the allograft and the skin graft in the long-term tolerant animal. The rejection of the skin grafts did not break tolerance to the musculoskeletal portion in any of the animals. Conclusions. All animals exhibited indefinite survival of the musculoskeletal portion of their allografts but only prolonged survival of the epidermis. The loss of the graft skin appears to be the result of an isolated immune reaction to the skin, and, in particular, the epidermis. This observation is further substantiated by the accelerated rejection of secondarily placed frozen donor skin grafts.


Microsurgery | 2000

Strategies for tolerance induction to composite tissue allografts

David W. Mathes; Mark A. Randolph; W. P. Andrew Lee

The emerging field of composite tissue transplantation offers the potential to replace lost tissues from cadaveric sources. Two major obstacles currently limit the future of composite tissue allotransplantation. The first is chronic rejection, attributed to both antibody deposition and cell‐mediated destruction of transplanted tissue. The second obstacle is complications associated with the chronic use of immunosuppressive agents. Our laboratory has been investigating several strategies to induce tolerance to limb tissue allografts to provide solutions to many of the current limitations in allotransplantation. Three strategies show promise in the ability to induce tolerance to organ allografts. The first involves genetic matching at the HLA loci followed by a short course of immunosuppression. The second is the application of a “mixed chimerism” regimen followed by transplantation. The third is costimulatory blockade using a short course of monoclonal antibodies, such as anti‐CD40 ligand and CTLA4‐Ig after transplantation. Inducing a state of tolerance to limb allografts would eliminate the need for chronic immunosuppression and may also prevent the onset of chronic rejection. The ability to induce allograft tolerance would greatly expand the indications for composite tissue transplantation.


Transplantation | 2001

Tolerance to musculoskeletal allografts with transient lymphocyte chimerism in miniature swine

Judy L. Bourget; David W. Mathes; G. Petur Nielsen; Mark A. Randolph; Yumi N. Tanabe; Vincent R. Ferrara; Anette Wu; Scott Arn; David H. Sachs; W. P. Andrew Lee

Background. Although transplantation of musculoskeletal allografts in humans is technically feasible, the adverse effects of long-term immunosuppression subject the patient to high risks for correcting a non-life-threatening condition. Achieving immunologic tolerance to musculoskeletal allografts, without the need for chronic immunosuppression, could expand the clinical application of limb tissue allografting. Tolerance to musculoskeletal allografts has been accomplished previously in miniature swine in our laboratory. Although stable, mixed chimerism has been suggested as the mechanism underlying long-term tolerance in a rat limb model, the mechanism of this tolerance induction has not been established. This report explores the possible relationship between hematopoietic chimerism and tolerance to musculoskeletal allografts in swine. Methods. Twelve miniature swine underwent vascularized musculoskeletal allograft transplantation from histocompatibility complex (MHC) matched, minor antigen-mismatched donors. Eight animals received a 12-day course of cyclosporine, one of which was excluded due to subtherapeutic levels. Four recipients were not immunosuppressed. Serial biopsies to assess graft viability and flow cytometry to assess chimerism were performed. Donor and third-party skin grafts were placed on recipients with surviving allografts greater than 100 days to validate tolerance. Results. Both groups developed early peripheral chimerism, but this chimerism became undetectable by postoperative day 19 in the cyclosporine group and by day 13 in the control group. Animals receiving cyclosporine developed permanent tolerance to their allografts, whereas those not receiving cyclosporine rejected their allografts in 6–9 weeks. Animals demonstrating tolerance to their bone allografts also demonstrated prolonged donor skin graft survival. Conclusions. Induction of tolerance to musculoskeletal allografts can be achieved in the MHC matched swine. Although hematopoietic chimerism is present in the immediate postoperative period, persistent, long-term chimerism does not seem to be necessary for maintenance of such tolerance.


Transplantation | 2002

Recipient bone marrow engraftment in donor tissue after long-term tolerance to a composite tissue allograft.

David W. Mathes; Mark A. Randolph; Judy L. Bourget; G. Petur Nielsen; Vincent R. Ferrera; J. Scott Arn; David H. Sachs; W. P. Andrew Lee

Background. An important component of a composite tissue limb allograft (CTA) is the vascularized bone marrow and bone marrow stroma, which when transplanted could create immediate marrow space and engraftment. We have previously demonstrated that tolerance to musculoskeletal allografts can be achieved with a 12-day course of cyclosporine without the presence of long-term peripheral donor cell chimerism. The objective of this study was to determine the fate of the donor bone marrow after transplantation of a limb allograft in a miniature swine model. Methods. CTAs from donor swine were heterotopically transplanted into six MHC-matched, minor-antigen–mismatched recipients, and a 12-day course of cyclosporine was given. Previous animals transplanted without cyclosporine rejected their grafts in less than 42 days. A non-MHC–linked marker, pig allelic antigen (PAA), was used to distinguish host and donor cells. Three PAA− animals received PAA+ CTAs, and three PAA+ animals received PAA− CTAs. Bone marrow was harvested from the donor limb grafts and the recipient and analyzed by flow cytometry and histology. Thymus, spleen, and mesenteric lymph nodes were also harvested from the recipient swine and evaluated for the presence of donor cells by flow cytometry. Results. All animals receiving cyclosporine demonstrated permanent tolerance to their allografts. Donor bone marrow cells were present in all grafts at the time of transplantation and during the immediate postoperative period. By 48 weeks, donor cells were no longer detectable within the marrow space of the allograft. In long-term animals host bone marrow cells replaced donor cells in the graft marrow space. No evidence of donor cell engraftment was found in recipient animals. Conclusion. This study demonstrates that in long-term tolerant recipients of musculoskeletal allografts there is no evidence of persistent donor bone marrow cells in the hematopoietic tissues of the graft or the host. Rather, the recipient’s bone marrow cells and lymphocytes repopulate the donor marrow space of the graft.


The Annals of Thoracic Surgery | 2000

Successful in situ treatment of an infected ascending aortic graft.

David W. Mathes; Michael J. Yaremchuk; Eric M. Isselbacher; Joren C. Madsen

Infection of an ascending aortic prosthesis is a grave complication associated with a high mortality. In most cases, extraanatomic bypass and removal of the infected vascular graft are not possible. Furthermore, the standard approach to this problem, which includes excision and replacement or debridement and repair of infected thoracic aortic grafts, carries a high early mortality. We report the successful treatment of this life-threatening complication using a conservative strategy in which the aortic prosthesis was salvaged by in situ disinfection followed by coverage with tissue flaps.


Transplantation | 2005

Long-term acceptance of renal allografts following prenatal inoculation with adult bone marrow

David W. Mathes; Mario G. Solari; Mark A. Randolph; G. Scott Gazelle; Kazuhiko Yamada; Christene A. Huang; David H. Sachs; W. P. Andrew Lee

Background. The aim was to investigate if intravascular in utero injection of adult bone marrow into swine fetuses could lead to macrochimerism and tolerance to the donor. Methods. Outbred Yorkshire sows and boars screening negative for MHC allele SLAc of MGH miniature swine were bred. A laparotomy was performed on the sows at 50 days gestation to expose the uterus. Bone marrow harvested from SLAcc miniature swine was T-cell depleted and injected intravascularly into seventeen fetuses. Flow cytometry was performed to detect donor cells (chimerism) in the peripheral blood after birth. Mixed lymphocyte reactions (MLR) and cell-mediated lympholysis (CML) assays were used to assess the response to donor MHC. Previously frozen skin grafts from the bone marrow donor were placed on the offspring from the first litter. Donor-matched renal transplant from SLAcc donors were performed on chimeric swine, with and without a short 12-day course of cyclosporine, and one nonchimeric littermate. Results. Nine inoculated offspring demonstrated donor cell chimerism in the peripheral blood and lymphohematopoietic tissues. All animals with detectable chimerism within the first three weeks were consistently nonreactive to donor MHC in vitro. Animals challenged with donor skin grafts displayed prolonged graft survival without producing antidonor antibodies. All chimeric animals accepted donor-matched kidney allografts, even one without cyclosporine. The kidney in the nonchimeric littermate rejected by day 21. Conclusions. Transplantation of allogeneic adult bone marrow into immunocompetent fetal recipients resulted in chimerism. In utero inoculation led to operational tolerance to the donor’s major histocompatibility antigens and long-term acceptance to organ allografts.


Transplant International | 2014

Stable mixed hematopoietic chimerism permits tolerance of vascularized composite allografts across a full major histocompatibility mismatch in swine

David W. Mathes; Mario G. Solari; Guy Scott Gazelle; Peter E. M. Butler; Anette Wu; Adam Nazzal; Gunnlauger P. Nielsen; Christene A. Huang; David H. Sachs; Wei Ping Andrew Lee; Mark A. Randolph

This study tested the hypothesis that vascularized composite allografts (VCA) could be accepted in a robust model of hematopoietic chimerism by injecting allogeneic bone marrow cells (BMC) into swine fetuses. Outbred Yorkshire sows and boars were screened to ensure the absence of the major histocompatibility (MHC) allele SLAcc of inbred MGH miniature swine and then mated. Bone marrow harvested from an SLAcc swine donor was T‐cell depleted and injected intravenously into the fetuses between days 50–55 of gestation. After birth, the piglets were studied with flow cytometry to detect donor cells and mixed lymphocyte reactions (MLR) and cell‐mediated lympholysis (CML) assays to assess their response to donor. Donor‐matched VCAs from SLAcc donors were performed on four chimeric and two nonchimeric swine. The results showed donor cell engraftment and multilineage macrochimerism after the in utero transplantation of adult BMC, and chimeric animals were unresponsive to donor antigens in vitro. Both control VCAs were rejected by 21 days and were alloreactive. Chimeric animals accepted the VCAs and never developed antidonor antibodies or alloreactivity to donor. These results confirm that the intravascular, in utero transplantation of adult BMC leads to donor cell chimerism and donor‐specific tolerance of VCAs across a full MHC barrier in this animal model.


Journal of Heart and Lung Transplantation | 2004

Detection of regulatory cells as an assay for allograft tolerance in miniature swine

Anette Wu; Kazuhiko Yamada; Christophe Baron; David W. Mathes; Leila Monajati; Parsia A. Vagefi; David H. Sachs

BACKGROUNDnThere is currently a great need for an in vitro assay to assess the presence of tolerance following allotransplantation to determine whether immunosuppressive medications can be discontinued. Our laboratory has recently developed an assay involving coculture inhibition of cell-mediated lympholysis that correlates with tolerance to allografts in swine leukocyte antigen (SLA) Class I-mismatched miniature swine. The potential for clinical application of this assay may depend on 2 important factors: (1) whether the assay can be used in the presence of immunosuppression; and (2) whether frozen-stored naive responder cells can be utilized.nnnMETHODSnLong-term tolerant MGH miniature swine that had accepted SLA Class I-mismatched kidney transplants after a 12-day course of cyclosporine or tacrolimus were studied. Two long-term tolerant and 2 naive control animals were treated with a clinically relevant dose of cyclosporine for 2 weeks (trough level 100 to 400 ng/ml) to simulate the ongoing chronic immunosuppression used in human recipients of allografts. Cells from tolerant or naive, recipient-matched animals were stimulated for 6 days with donor or third-party SLA. These primed cells were then cocultured with naive unstimulated recipient major histocompatibility complex (MHC)-matched responders and irradiated stimulators. Responder cells were tested both fresh and frozen.nnnRESULTSnSuppression of cytotoxic responses of naive responder cells was observed in all coculture assays using cells from tolerant animals primed against donor antigen in vitro, but not in assays using similarly primed cells from naive animals. Responder cells from tolerant animals receiving immunosuppression had a suppressive activity similar to that from cells of the same animals not receiving immunosuppression. Similar suppression was also observed in coculture assays using either fresh or frozen naive responder cells.nnnCONCLUSIONSnThis coculture assay appears to correlate with the presence of tolerance under conditions applicable to the clinical setting. The assay appears to identify peripheral regulatory mechanisms of tolerance in allogeneic transplant recipients, and therefore may provide an approach for determining an appropriate timepoint at which to test withdrawal of immunosuppressive medications.


Journal of The American Society for Surgery of The Hand | 2003

New trends and future directions of research in hand and composite tissue allotransplantation

François Petit; Alicia B. Minns; Shehan Hettiaratchy; David W. Mathes; Mark A. Randolph; W. P. Andrew Lee

Abstract Hand and composite tissue allotransplantation (CTA) holds great potential for reconstructive surgery but its development currently is limited by the side effects of the immunosuppressive drugs. Induction of specific tolerance, a situation in which the recipient does not mount an immune response against the allograft but remains fully immunocompetent, holds exciting promise. The generation of mixed hematopoietic chimerism by infusing the recipient with donor bone marrow cells has been shown to induce tolerance without chronic immunosuppression. Genetic matching of the donor and the recipient is another option for transplanting composite tissues with only an initial course of immunosuppression. Experiments showed long-term survival of musculoskeletal allografts between major histocompatibility complex (MHC)-matched miniature swine. Finally, new immunosuppressive agents with a more targeted action will reduce side effects and may prevent the development of chronic rejection. Skin-specific immunosuppression is particularly useful for limb transplants because skin, regarded as the most antigenic component, is easily accessible to topical or irradiation therapies.


American Journal of Surgery | 2017

Re-excision rates after breast conserving surgery following the 2014 SSO-ASTRO guidelines

Alicia A. Heelan Gladden; Sharon B. Sams; Ana Gleisner; Christina Finlayson; Nicole Kounalakis; Patrick Hosokawa; Regina J. Brown; Tae Chong; David W. Mathes; Colleen Murphy

BACKGROUNDnIn 2014, SSO-ASTRO published guidelines which recommended no ink on tumor as adequate margins for patients undergoing breast conservation for invasive breast cancer. In 2016, new SSO-ASTRO-ASCO guidelines recommended 2xa0mm margins for DCIS. We evaluated whether these guidelines affected re-excision rates at our institution.nnnMETHODSnPatients treated with breast conservation surgery from January 1, 2010-March 1, 2016 were identified. Re-excision rates, tumor characteristics, and presence of residual disease were recorded. The 2016 guidelines were retrospectively applied to the same cohort and expected re-excision rates calculated.nnnRESULTSnRe-excision rates did not significantly decline before and after 2014 guideline adoption (11.9% before, 10.9% after; pxa0=xa00.65) or when the 2016 guidelines were retrospectively applied (8.4%; pxa0=xa00.10).nnnCONCLUSIONSnThe 2014 and 2016 guidelines had minimal impact on our re-excision rates, as most re-excisions were done for DCIS and 2016 guidelines supported our prior institutional practices of 2xa0mm margins for these patients.

Collaboration


Dive into the David W. Mathes's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeff Chang

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Scott S. Graves

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

W. P. Andrew Lee

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rainer Storb

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Tiffany Butts

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge